RxDoctor Payments DataLook up a doctor →

Ronald Bloom, MD

Cardiovascular Disease · Bloomfield, CTNPI 1548238835

Payments from drug & device makers

$18,284in general payments, 2019–2025

Across 760 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • Amgen$1K
  • Boehringer Ingelheim$939
  • plus $11K from 54 others

What the payments were for

  • Travel & lodging$1,0346%
  • Food & beverage$16,97093%
  • Education$2812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)10$1,714
AstraZeneca60$1,366
Johnson & Johnson82$1,274
Pfizer65$1,233
Amgen49$1,186
Boehringer Ingelheim36$939
Amarin Pharma, Inc.46$910
E.r. Squibb & Sons, L.L.C.51$854
Novartis32$705
Bayer19$683
Novo Nordisk24$667
Abbott17$610
Sanofi-aventis U.S. LLC20$557
Boston Scientific13$512
Esperion Therapeutics, Inc.22$507
Kowa Pharmaceuticals America, Inc.34$414
Merck23$392
Scpharmaceuticals Inc.17$288
Alnylam Pharmaceuticals Inc.11$261
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$260
Astellas Pharma US Inc5$251
Teva Pharmaceuticals USA, Inc.11$229
Bausch Health US, LLC15$228
Lilly USA, LLC5$190
Edwards Lifesciences1$159
Actelion Pharmaceuticals US, Inc.7$139
Abiomed4$130
Celltrion USA Inc.1$124
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$117
Lexicon Pharmaceuticals, Inc.5$96
GSK4$94
Kiniksa Pharmaceuticals International, PLC3$90
Antares Pharma, Inc.3$68
Akcea Therapeutics, Inc.3$67
Kiniksa Pharmaceuticals, Ltd.3$66
Regeneron Healthcare Solutions, Inc.3$65
Sanofi3$58
Impulse Dynamics (USA) Inc.2$53
Bardy Diagnostics, Inc.7$49
Biohaven Pharmaceutical Holding Company Ltd.2$47
Vifor Pharma, Inc.3$47
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$45
Lundbeck LLC2$42
Bridgebio Pharma, Inc.2$41
Alkermes, Inc.2$37
Avanir Pharmaceuticals, Inc.2$34
Insightec,inc1$31
Chiesi USA, Inc.1$30
Azurity Pharmaceuticals, Inc.1$28
Evoke Pharma, Inc.2$26
Biohaven Pharmaceuticals, Inc.1$26
Corcept Therapeutics1$25
Sumitomo Pharma America, Inc.1$23
Neurocrine Biosciences, Inc.1$23
Baxter Healthcare1$23
Medicomp Inc1$23
Otsuka America Pharmaceutical, Inc.1$20
Idorsia Pharmaceuticals US Inc1$19
Optinose US, Inc.1$17
Arbor Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,284 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$100,804
Medicare patients
394
Services billed
1,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$336,837
XareltoRivaroxaban87$124,373
EntrestoSacubitril/Valsartan61$76,718
JardianceEmpagliflozin32$35,483
Repatha SureclickEvolocumab26$23,142
VascepaIcosapent Ethyl12$8,297
Metoprolol Succinate388$5,982
Rosuvastatin Calcium362$4,087
Atorvastatin Calcium311$3,480
Ezetimibe104$2,635
Amlodipine Besylate291$1,930
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,740
Nebivolol Hcl32$1,721
Ranolazine ErRanolazine11$1,720
Losartan Potassium143$1,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,233$336,837252 claims
Johnson & JohnsonXarelto$1,274$124,37387 claims
NovartisEntresto$705$76,71861 claims
Boehringer IngelheimJardiance$939$35,48332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →